GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MAKO Surgical Corporation (FRA:4M6) » Definitions » ROC %

MAKO Surgical (FRA:4M6) ROC % : -125.99% (As of Sep. 2013)


View and export this data going back to . Start your Free Trial

What is MAKO Surgical ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. MAKO Surgical's annualized return on capital (ROC %) for the quarter that ended in Sep. 2013 was -125.99%.

As of today (2024-06-25), MAKO Surgical's WACC % is 0.00%. MAKO Surgical's ROC % is 0.00% (calculated using TTM income statement data). MAKO Surgical earns returns that do not match up to its cost of capital. It will destroy value as it grows.


MAKO Surgical ROC % Historical Data

The historical data trend for MAKO Surgical's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MAKO Surgical ROC % Chart

MAKO Surgical Annual Data
Trend Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -246.72 -135.04 -99.72 -62.02 -46.53

MAKO Surgical Quarterly Data
Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -53.57 -29.29 -44.32 -69.12 -125.99

MAKO Surgical ROC % Calculation

MAKO Surgical's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2012 is calculated as:

ROC % (A: Dec. 2012 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2011 ) + Invested Capital (A: Dec. 2012 ))/ count )
=-27.064 * ( 1 - -0.26% )/( (50.288 + 66.347)/ 2 )
=-27.1343664/58.3175
=-46.53 %

where

MAKO Surgical's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2013 is calculated as:

ROC % (Q: Sep. 2013 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2013 ) + Invested Capital (Q: Sep. 2013 ))/ count )
=-63.576 * ( 1 - 0% )/( (53.965 + 46.961)/ 2 )
=-63.576/50.463
=-125.99 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2013) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MAKO Surgical  (FRA:4M6) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, MAKO Surgical's WACC % is 0.00%. MAKO Surgical's ROC % is 0.00% (calculated using TTM income statement data). MAKO Surgical earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


MAKO Surgical ROC % Related Terms

Thank you for viewing the detailed overview of MAKO Surgical's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


MAKO Surgical (FRA:4M6) Business Description

Traded in Other Exchanges
N/A
Address
MAKO Surgical Corporation was incorporated in Delaware in November 2004. The Company is a medical device company that markets its advanced robotic arm solution, joint specific applications for the knee and hip, and orthopedic implants for orthopedic procedures. It offers MAKOplasty, an innovative, restorative surgical solution that enables orthopedic surgeons to consistently, reproducibly and precisely treat patient specific, osteoarthritic disease. The Company currently offers MAKOplasty Partial Knee Arthroplasty, or MAKOplasty PKA, and MAKOplasty Total Hip Arthroplasty, or MAKOplasty THA. MAKOplasty PKA, which requires extraction and replacement of the entire joint, enables resurfacing of one or two specific diseased compartments of the joint, preserving significantly more soft tissue and healthy bone of the knee. MAKOplasty procedures are enabled through its proprietary technology consisting of the components which includes its RIO system, its MAKOplasty applications, and its RESTORIS family of implant systems. The centerpiece of MAKOplasty is the RIO system, its proprietary robotic arm, interactive, orthopedic system, that provides both pre-operative and intra-operative guidance to the orthopedic surgeon, enabling tissue sparing bone removal and accurate implant insertion and alignment. The RIO system consists of two elements: a tactile robotic arm utilizing an integrated bone cutting instrument and a patient specific visualization component. The RIO system, version 2.0 of its Tactile Guidance System, or TGS, represents an important expansion from its first generation TGS, enabling and expanding the MAKOplasty PKA application to multicompartmental resurfacing procedures, allowing orthopedic surgeons to treat degenerative knee osteoarthritis from early-stage, unicompartmental degeneration through mid-stage, multicompartmental degeneration with a modular knee implant system, as well as enabling the MAKOplasty THA application. The Company's MAKOplasty PKA application enables surgeons to isolate and resurface just one or two specific diseased compartments of the joint through a minimally invasive incision, preserving significantly more soft tissue and healthy bone of the knee. The MAKOplasty knee resurfacing procedure is performed by the surgeon using the surgical planning and execution software integrated into its patient specific visualization system. The Company's MAKOplasty THA application utilizes the RIO system's tactile, visual and auditory feedback to assist the surgeon in preparing the acetabulum (hip socket) for optimal placement of the acetabular cup implant. The MAKOplasty THA application allows the surgeon to preoperatively plan the placement of the hip implants on a three dimensional image of a pre-operative CT scan. Its RESTORIS family of knee implants is designed to enable minimally invasive restoration of one or two of the diseased compartments of the knee joint. Its RESTORIS family of knee implants for use in si

MAKO Surgical (FRA:4M6) Headlines

No Headlines